Leitner P, Serfling R
Klinikum Berlin-Buch, Psychiatrische Klinik, Berlin.
Psychiatr Prax. 1993 Nov;20(6):207-10.
The interest in the psychopharmacological treatment of the borderline personality disorder (BPS) has been steadily increased in the last years. There isn't, however, any investigation, which has proved the existence of a specific "Anti-Borderline-Drug" yet. There are, however, identifiable drug-responsive syndromes. The description by Coccaro and Karoussi (1991) of a syndrome of affective instability (abnormalities in the brain's adrenergic and cholinergic systems, respond to carbamazepine and lithium), transient psychotic phenomena (abnormalities in the central dopaminergic systems, respond to low-dose neuroleptics) and impulsive, aggressive behaviour (abnormalities in the central serotonergic systems, respond to serotonergic agents) seems to be very promising in this regard.
近年来，对边缘型人格障碍（BPS）进行心理药物治疗的关注度一直在稳步上升。然而，目前尚无任何研究能够证明存在一种特定的“抗边缘型人格障碍药物”。不过，确实存在一些可识别的药物反应综合征。在这方面，科卡罗和卡鲁西（1991年）对一种情感不稳定综合征（大脑肾上腺素能和胆碱能系统异常，对卡马西平和锂有反应）、短暂性精神病现象（中枢多巴胺能系统异常，对低剂量抗精神病药物有反应）以及冲动、攻击行为（中枢5-羟色胺能系统异常，对5-羟色胺能药物有反应）的描述似乎很有前景。
